Following on from information provided to NICE by the company in December 2017, the appraisal of Multiple myeloma – bortezomib (consolidation therapy) [ID529] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 529 |
| Referral date | 01 May 2012 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in December 2017, the appraisal of Multiple myeloma – bortezomib (consolidation therapy) [ID529] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 7 November 2014 |
The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for bortezomib in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
| 20 July 2012 | Please note that following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established. |
For further information on our processes and methods, please see our CHTE processes and methods manual